Allergic Rhinitis (AR) is becoming an increasingly prevalent condition, with the most common form being moderate to severe in nature. According to the European Academy of Allergy and Clinical Immunology (EAACI), 50% of Europeans will suffer from an allergy by 2027. A GlobalData epidemiological study estimated that about one in seven people in the US have been diagnosed with AR at some point in their life, or about 43 million people. This rate appears to be on the rise, and is expected to reach over 46 million by 2024.
Pollen seasons are set to last longer and to become increasingly more intense, which means the severity of symptoms experienced by polysensitized patients is set to increase. It has been postulated that the changing environment, particularly the trend of global warming, may lead to increased pollen exposure and expanded environments for the growth of numerous plant species. The prevalence of asthma and allergic diseases has increased dramatically during the past few decades, the incidence of AR in the US population has increased from 10% in 1970 to 30% in 2000. This increase in the AR prevalence will be a strong driver of the growth of this market, as the AR patient pool will increase, leading to higher consumption of medications used to treat the disease.
